PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
An open‑source COVID‑19 vaccine, PVX‑001, has entered its first‑in‑human Phase 1 trial. Developed by a collaborative research group, the vaccine uses a novel platform that allows community‑driven modifications. The trial will assess safety and immune response in a small cohort of volunteers. If successful, it could pave the way for rapid, adaptable vaccine development. The study will also monitor adverse events.